Loading...
XNASSTOK
Market cap562mUSD
Jan 24, Last price  
10.62USD
1D
0.19%
1Q
-10.83%
IPO
-59.15%
Name

Stoke Therapeutics Inc

Chart & Performance

D1W1MN
P/E
P/S
64.07
EPS
Div Yield, %
Shrs. gr., 5y
13.35%
Rev. gr., 5y
%
Revenues
9m
-29.22%
0000012,405,0008,780,000
Net income
-105m
L+12.45%
-5,558,000-12,521,000-28,524,000-50,611,000-84,711,000-93,110,000-104,699,000
CFO
-81m
L+154.40%
-5,384,000-10,964,000-31,055,000-42,221,000-66,907,000-31,866,000-81,067,000
Earnings
Mar 24, 2025

Profile

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
IPO date
Jun 19, 2019
Employees
117
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
8,780
-29.22%
12,405
 
Cost of revenue
123,553
120,296
Unusual Expense (Income)
NOPBT
(114,773)
(107,891)
NOPBT Margin
Operating Taxes
(7,957)
Tax Rate
NOPAT
(114,773)
(99,934)
Net income
(104,699)
12.45%
(93,110)
9.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
52,081
46,408
BB yield
-22.51%
-12.93%
Debt
Debt current
2,388
2,359
Long-term debt
2,062
5,076
Deferred revenue
33,074
36,856
Other long-term liabilities
4,884
2,968
Net debt
(196,944)
(222,729)
Cash flow
Cash from operating activities
(81,067)
(31,866)
CAPEX
(1,616)
(3,962)
Cash from investing activities
105,946
(45,882)
Cash from financing activities
53,007
46,409
FCF
(115,779)
(102,284)
Balance
Cash
201,394
229,595
Long term investments
569
Excess cash
200,955
229,544
Stockholders' equity
(401,868)
(298,321)
Invested Capital
601,453
528,070
ROIC
ROCE
EV
Common stock shares outstanding
43,995
38,897
Price
5.26
-43.01%
9.23
-61.53%
Market cap
231,413
-35.54%
359,023
-59.27%
EV
34,469
136,294
EBITDA
(112,304)
(106,345)
EV/EBITDA
Interest
3,122
Interest/NOPBT